Abstract

BackgroundThe present study compares antiepileptic drugs and aromatase (CYP19) inhibitors for chemical and structural similarity. Human aromatase is well known as an important pharmacological target in anti-breast cancer therapy, but recent research demonstrates its role in epileptic seizures, as well. The current antiepileptic treatment methods cause severe side effects that endanger patient health and often preclude continued use. As a result, less toxic and more tolerable antiepileptic drugs (AEDs) are needed, especially since every individual responds differently to given treatment options.MethodsThrough a pharmacophore search, this study shows that a model previously designed to search for new classes of aromatase inhibitors is able to identify antiepileptic drugs from the set of drugs approved by the Food and Drug Administration. Chemical and structural similarity analyses were performed using five potent AIs, and these studies returned a set of AEDs that the model identifies as hits.ResultsThe pharmacophore model returned 73% (19 out of 26) of the drugs used specifically to treat epilepsy and approximately 82% (51 out of 62) of the compounds with anticonvulsant properties. Therefore, this study supports the possibility of identifying AEDs with a pharmacophore model that had originally been designed to identify new classes of aromatase inhibitors. Potential candidates for anticonvulsant therapy identified in this manner are also reported. Additionally, the chemical and structural similarity between antiepileptic compounds and aromatase inhibitors is proved using similarity analyses.ConclusionsThis study demonstrates that a pharmacophore search using a model based on aromatase inhibition and the enzyme's structural features can be used to screen for new candidates for antiepileptic therapy. In fact, potent aromatase inhibitors and current antiepileptic compounds display significant - over 70% - chemical and structural similarity, and the similarity analyses performed propose a number of antiepileptic compounds with high potential for aromatase inhibition.

Highlights

  • The present study compares antiepileptic drugs and aromatase (CYP19) inhibitors for chemical and structural similarity

  • Some aromatase inhibitors (AIs) - like letrozole, for example, which has been approved for the treatment of breast cancer by the Food and Drug Administration (FDA) [6] - have been clinically successful in treating epilepsy in men [7]

  • All in all, this study has shown that a pharmacophore model [18] - originally derived from potent AIs and from the aromatase active site structure - can be used to screen for antiepileptic drugs (AEDs)

Read more

Summary

Introduction

The present study compares antiepileptic drugs and aromatase (CYP19) inhibitors for chemical and structural similarity. Less toxic and more tolerable antiepileptic drugs (AEDs) are needed, especially since every individual responds differently to given treatment options. Harmful side effects seem to be the most significant factor in the approximately 35% long-term or 3-year retention rate for all new AEDs [1]. Less toxic and more tolerable AEDs are needed, especially since every individual. Aminoglutethimide, a drug that had been originally pursued for anticonvulsant therapy, eventually became the first-generation aromatase inhibitor [4]. Some aromatase inhibitors (AIs) - like letrozole, for example, which has been approved for the treatment of breast cancer by the Food and Drug Administration (FDA) [6] - have been clinically successful in treating epilepsy in men [7]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.